TNF receptor superfamily member 9 (TNFRSF9)

Overview

TNFRSF9 encodes 4-1BB, also known as CD137, a member of the tumor necrosis factor receptor superfamily. It is an inducible cell-surface costimulatory receptor expressed primarily on activated T cells and other immune cells, where it helps amplify immune activation, support cell survival, and promote effector function. Because of these properties, TNFRSF9 is widely studied in cancer immunology and immunotherapy as both a biomarker of immune activation and a therapeutic target.

In biomedical research, TNFRSF9 is especially relevant to CAR-T-cell engineering and 4-1BB agonistic monoclonal antibody development. The receptor is used as a costimulatory module in many chimeric antigen receptor designs, and its signaling has been investigated for effects on T-cell persistence, metabolic fitness, proliferation, and antitumor activity. It is also being explored in the context of immune checkpoint modulation and inflammatory immune states, including regulatory T-cell phenotypes.

Recent Publications Focus

Recent studies have focused on TNFRSF9/CD137 as an immunoregulatory target in T cells, particularly in regulatory T-cell biology and immune-related inflammation. In a NOD mouse model of type 1 diabetes, Foxp3+ Treg-specific deletion of CD137 reduced circulating soluble CD137, accelerated diabetes, and was associated with increased clonal expansion and differentiation of effector T cells in pancreatic islets 42412561Jul. The same study found that CD137-deficient Foxp3+ Tregs were less frequent in islets and showed impaired differentiation toward a suppressive phenotype, while restoring soluble CD137 reduced islet T-cell activation and mitigated diabetes acceleration 42412561Jul. Together, these findings indicate that both soluble and membrane CD137 expressed by Foxp3+ Tregs contribute to immune restraint in autoimmune diabetes 42412561Jul.

TNFRSF9 has also been implicated in atypical regulatory T-cell states in immune checkpoint inhibitor-induced inflammatory arthritis. A recent report described a subset of regulatory T cells coexpressing CD137 and IL6R, termed atypical Tregs, that were enriched in patients with immune checkpoint inhibitor-induced inflammatory arthritis and displayed reduced suppressive capacity with a Th17-like proinflammatory phenotype 42383349Jul. These cells were associated with more severe arthritis but also improved cancer outcomes, and off-label tocilizumab treatment reduced atypical Treg abundance while alleviating arthritis in a small cohort, suggesting a potential therapeutic strategy for irAEs involving this CD137-positive Treg population 42383349Jul.

Several publications examined TNFRSF9 in the context of CAR T-cell therapy and costimulatory signaling. One study showed that CAR T-cell costimulatory domains shape memory fate acquisition through asymmetric cell division, with 4-1BB CAR T cells exhibiting greater transcriptional, metabolic, and epigenetic divergence between daughter cells and a persistence-prone fate compared with CD28 CAR T cells 42332264Jun. Related work demonstrated that endogenous CD28 signaling cooperates with 4-1BB costimulation to support CAR T-cell metabolic fitness, proliferation, and sustained antitumor activity in myeloma and lymphoma models 41627211Feb41848361Mar. In a clinical manufacturing and expanded-access analysis of idecabtagene vicleucel, out-of-specification products were most commonly associated with high CD137 activation or low infused dose, yet these products still showed consistent safety and efficacy, with cytokine release syndrome and neurological toxicities reported alongside objective responses 41894689Mar.

Beyond CAR T-cell therapy, TNFRSF9-related signaling was also studied in the pancreatic tumor microenvironment. In a PDAC model, pharmacologic inhibition of MAP4K4 reduced tumor-infiltrating macrophages and neutrophils, increased T-cell counts, and decreased expression of the 4-1BB gene in peripheral and tumor-infiltrating T cells 41707980Feb. Combining the MAP4K4 inhibitor GNE-495 with a 4-1BB agonistic monoclonal antibody produced maximal cytotoxic T-cell infiltration, tumor regression, and improved survival in KPC mice, supporting a role for TNFRSF9-directed costimulation in antitumor immunity within the tumor microenvironment 41707980Feb.

What Changes, What Holds

1. CD137 on Foxp3+ Tregs helps restrain autoimmune diabetes
NEW DIRECTION New work extends TNFRSF9 beyond a general activation marker to a functional brake within regulatory T-cell biology, specifically in autoimmune diabetes 42412561Jul. That does not overturn the baseline role in immune activation, but it adds a disease-relevant suppressive function for both membrane and soluble CD137 on Foxp3+ Tregs. The result is preclinical and mechanistic, so it should be treated as a strong direction for follow-up rather than a settled therapeutic rule.

2. CD137-positive atypical Tregs may link checkpoint blockade inflammation and tumor control
NEW DIRECTION Recent data place TNFRSF9 in an inflammatory regulatory-T-cell state that the Overview does not cover: a CD137+IL6R+ subset with reduced suppression and Th17-like features in checkpoint inhibitor–associated arthritis 42383349Jul. That broadens CD137 biology into irAE pathogenesis and suggests a possible biomarker or treatment handle, while also creating a tension between inflammation control and cancer benefit. The evidence is early and correlative, so the therapeutic implications remain provisional.

3. 4-1BB costimulation remains central to CAR-T persistence, fitness, and manufacturing interpretation
REINFORCES These studies sharpen the established CAR-T role of TNFRSF9 by showing how 4-1BB signaling shapes memory fate, metabolic competence, and sustained antitumor activity 42332264Jun41627211Feb41848361Mar. They also suggest that high CD137 activation can complicate manufacturing classification without necessarily negating clinical utility 41894689Mar. Nothing here displaces the baseline; instead, the work strengthens the case that 4-1BB is a key design variable and a useful activation readout.

4. 4-1BB-directed costimulation can be leveraged to improve pancreatic tumor immunity
REINFORCES The pancreatic tumor microenvironment data fit the established view of TNFRSF9 as an antitumor immunotherapy target, showing that lowering MAP4K4 activity can reduce 4-1BB expression while combining that inhibitor with a 4-1BB agonist enhances cytotoxic infiltration and survival 41707980Feb. This is not a new role for CD137 so much as a new context in which its agonism appears useful. The main takeaway is that TNFRSF9-directed costimulation may be most effective when paired with interventions that relieve myeloid suppression.

Overview update candidates: CD137 as a suppressive factor in Foxp3+ Tregs during autoimmune diabetes; CD137+IL6R+ atypical Tregs in checkpoint inhibitor–induced inflammatory arthritis.